Diagnostic test: calprotectin (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04183608 (ClinicalTrials.gov) | January 14, 2020 | 28/10/2019 | A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab | An Open-label Randomized Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating adaLimumab: The CONTROL Trial | Ulcerative Colitis | Drug: Adalimumab;Diagnostic Test: Calprotectin;Other: e-Monitoring;Other: Therapy Education | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | AbbVie | Recruiting | 18 Years | 75 Years | All | 238 | Phase 4 | France |